The phrase "afford potent" is not correct and does not convey a clear meaning in written English.
It seems to be an incomplete or incorrect expression, and without additional context, it is difficult to determine its intended use.
Example: "The new policy may afford potent benefits to the community."
Alternatives: "provide strong" or "offer significant".
Structure-based design was utilized to guide the early stage optimization of a substrate-like inhibitor to afford potent peptidomimetic inhibitors of the channel-activating protease prostasin.
These cases "afford potent precedence in the privacy field," he wrote, adding: "I may have to push myself a bit, but I would not be offended by the extension of privacy concepts to the point presented in the present case".
In this paper we report a new class of molecular framework combining the pharmacophoric features of DPP4 inhibitors with those of ACE inhibitors to afford potent dual inhibitors of DPP4 and ACE.
A series of 2- 6-phenyl-1H indazol-3-yl)-1H-benzo[d]imidazoles with initial high crossover to CDK-2- 6-phenyl-1Himized to afford potent and selective inhibitors of protein kinase c-zeta (PKC-ζ).
This should lead to nanomolar TbNMT potencies (as previously observed), which should afford potent parasite cell activities at T. brucei.[ 8, 9] A suitable group could be designed, with correct vector and linker to achieve this interaction, as seen in the benzomorpholinone series hit-to-lead strategy.
Design of a second generation of HDACs was based upon these data affording potent HDACs such as LAQ824 and PDX101 currently under phase I clinical trials.
Treatment of mice with Dex (10 µg intraperitoneally daily from day 2) afforded potent antiarthritic effects highly attenuated in the knockouts: macroscopic changes were mirrored by histopathological findings and pro-inflammatory gene (eg, Nos2) expression.
Compounds from the benzomorpholinone series afforded potent antiparasitic cell activities (T. brucei EC50: 0.007 μ m for 44); they display promising in vitro DMPK profiles, showing this series has the potential to be optimised further to deliver orally active antiparasitic compounds.
More recently, another mGlu5 partial antagonist 5-PEP 20 was converted into a potent, full NAM by the addition of a methyl group in the 3-position 19; in contrast, addition of either a 4-methyl group 21 or an aminomethyl moiety 22 afforded potent mGlu5 PAMs.
A non-selective inhibitor (1) of FMS-like tyrosine kinase-3 (FLT3) was identified by fragment screening and systematically modified to afford a potent and selective inhibitor 26.
The 2- and 7-substituents in the pyrazolo[1,5-a]pyridine subunit markedly influence the PDE-inhibitory profile and can be adjusted to afford either potent PDE4-selective inhibitors or dual PDE3/4 inhibitors.
